Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase

被引:126
作者
Albrecht, Brian K. [1 ]
Harmange, Jean-Christophe [1 ]
Bauer, David [1 ]
Berry, Loren [1 ]
Bode, Christiane [1 ]
Boezio, Alessandro A. [1 ]
Chen, April [1 ]
Choquette, Deborah [1 ]
Dussault, Isabelle [2 ]
Fridrich, Cary [1 ]
Hirai, Satoko [1 ]
Hoffman, Doug [2 ]
Larrow, Jay F. [1 ]
Kaplan-Lefko, Paula [2 ]
Lin, Jasmine [1 ]
Lohman, Julia [1 ]
Long, Alexander M. [1 ]
Moriguchi, Jodi [2 ]
O'Connor, Anne [1 ]
Potashman, Michele H. [1 ]
Reese, Monica [2 ]
Rex, Karen [2 ]
Siegmund, Aaron [2 ]
Shah, Kavita [1 ]
Shimanovich, Roman [1 ]
Springer, Stephanie K. [1 ]
Teffera, Yohannes [1 ]
Yang, Yajing [2 ]
Zhang, Yihong [2 ]
Bellon, Steven F. [1 ]
机构
[1] Amgen Inc, Cambridge, MA 02139 USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
D O I
10.1021/jm800043g
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tumorigenesis is a multistep process in which oncogenes play a key role in tumor formation, growth, and maintenance. MET was discovered as an oncogene that is activated by its ligand, hepatocyte growth factor. Deregulated signaling in the c-Met pathway has been observed in multiple turner types. Herein we report the discovery of potent and selective triazolopyridazine small molecules that inhibit c-Met activity.
引用
收藏
页码:2879 / 2882
页数:4
相关论文
共 10 条
[1]   Targeting tyrosine kinases in cancer: The second wave [J].
Baselga, Jose .
SCIENCE, 2006, 312 (5777) :1175-1178
[2]   C-met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations [J].
Bellon, Steven F. ;
Kaplan-Lefko, Paula ;
Yang, Yajing ;
Zhang, Yihong ;
Moriguchi, Jodi ;
Rex, Karen ;
Johnson, Carol W. ;
Rose, Paul E. ;
Long, Alexander M. ;
O'Connor, Anne B. ;
Gu, Yan ;
Coxon, Angela ;
Kim, Tae-Seong ;
Tasker, Andrew ;
Burgess, Teresa L. ;
Dussault, Isabelle .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (05) :2675-2683
[3]   Met, metastasis, motility and more [J].
Birchmeier, C ;
Birchmeier, W ;
Gherardi, E ;
Vande Woude, GF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925
[4]  
Christensen JG, 2003, CANCER RES, V63, P7345
[5]   Hereditary papillary renal carcinoma type I [J].
Dharmawardana, PG ;
Giubellino, A ;
Bottaro, DP .
CURRENT MOLECULAR MEDICINE, 2004, 4 (08) :855-868
[6]   MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].
Engelman, Jeffrey A. ;
Zejnullahu, Kreshnik ;
Mitsudomi, Tetsuya ;
Song, Youngchul ;
Hyland, Courtney ;
Park, Joon Oh ;
Lindeman, Neal ;
Gale, Christopher-Michael ;
Zhao, Xiaojun ;
Christensen, James ;
Kosaka, Takayuki ;
Holmes, Alison J. ;
Rogers, Andrew M. ;
Cappuzzo, Federico ;
Mok, Tony ;
Lee, Charles ;
Johnson, Bruce E. ;
Cantley, Lewis C. ;
Janne, Pasi A. .
SCIENCE, 2007, 316 (5827) :1039-1043
[7]   TYROSINE KINASE RECEPTOR INDISTINGUISHABLE FROM THE C-MET PROTEIN [J].
GIORDANO, S ;
PONZETTO, C ;
DIRENZO, MF ;
COOPER, CS ;
COMOGLIO, PM .
NATURE, 1989, 339 (6220) :155-156
[8]   Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 [J].
Smolen, GA ;
Sordella, R ;
Muir, B ;
Mohapatra, G ;
Barmettler, A ;
Archibald, H ;
Kim, WJ ;
Okimoto, RA ;
Bell, DW ;
Sgroi, DC ;
Christensen, JG ;
Settleman, J ;
Haber, DA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (07) :2316-2321
[9]  
Zhang F. -J., 2005, Preparation of triazolotriazines as cMet modulators for treating cancer, Patent No. [WO 2005010005A1, 2005010005]
[10]   An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms [J].
Zou, Helen Y. ;
Li, Qiuhua ;
Lee, Joseph H. ;
Arango, Maria E. ;
McDonnell, Scott R. ;
Yamazaki, Shinji ;
Koudriakova, Tatiana B. ;
Alton, Gordon ;
Cui, Jingrong J. ;
Kung, Pei-Pei ;
Nambu, Mitchell D. ;
Los, Gerrit ;
Bender, Steven L. ;
Mroczkowski, Barbara ;
Christensen, James G. .
CANCER RESEARCH, 2007, 67 (09) :4408-4417